ALLK Stock Discussion

Allakos Inc. Description

Allakos, Inc. is a clinical-stage biotechnology company, which is engaged in developing antibodies that selectively target mast cells and eosinophils. The Company's antibodies target receptor molecules present on the surface of immune effector cells, which are involved in allergy, inflammation and tissue damage. Its lead program is AK002, which is an antibody that targets Siglec-8, an inhibitory receptor found on eosinophils and mast cells. The Company's AK002 is used in the treatment of various diseases with abnormal proliferation of mast cells, including eosinophilic gastritis (EG), indolent systemic mastocytosis, urticaria and allergic conjunctivitis.

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biology Disease Immunology Immune System Antibodies Inflammation Antibody Cell Biology Allergy Allergic Conjunctivitis Mast Cell Mastocytosis Systemic Mastocytosis Eosinophil